Stay updated on Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Sign up to get notified when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.
Latest updates to the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayChange DetectedA new resource titled 'Helpful Links Provided by Andrea Ardizzoni' has been added, featuring information on Cabozantinib (XL184), highlighting its role as a novel MET and VEGFR2 inhibitor that suppresses metastasis, angiogenesis, and tumor growth.SummaryDifference0.6%
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has expanded to include 11 locations, and the revision has been updated from v2.9.7 to v2.10.0.SummaryDifference0.2%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.0%
- Check21 days agoChange DetectedThe website has removed information about Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, and helpful links provided by Andrea Ardizzoni from the University of Bologna.SummaryDifference0.6%
- Check24 days agoChange DetectedThe value in the web page has been updated to include an additional DOI (doi: 10.1200/JCO.2016.67.2352) for the publication by Masters GA et al. This change likely reflects an erratum or additional information added to the original publication.SummaryDifference0.0%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.SummaryDifference0.0%
Stay in the know with updates to Cabozantib in RET+ NSCLC: Phase II Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantib in RET+ NSCLC: Phase II Clinical Trial page.